Weight loss
EnteroMedics releases positive results from VBLOC pivotal trial
EnteroMedics (NSDQ:ETRM) revealed results for the 1st 18 months of its 5-year ReCharge pivotal trial for its VBLOC therapy, an implanted neurostimulator designed to help prevent obesity.
Obesity: Allergan finalizes Lap-Band division sale
Sleep apnea big concern among overweight pilots, aviation regulators say
Federal aviation regulators are launching a new screening program to week out pilots with sleep apnea, a condition that they noted is "nearly universal" in adults with a body mass index of 40 or higher.
The FAA plans to ground any pilots diagnosed with OSA until they are successfully treated, as determined by a board-certified sleep specialist, according to a memo from the agency.
EnteroMedics Q3 losses widen as company continues chasing FDA approval
Weight loss: Docs unveil new study of bariatric surgery in teens | MassDevice.com On Call
MASSDEVICE ON CALL — Researchers this week unveiled the 1st early results from a benchmark clinical trial evaluating bariatric weight-loss surgery in severely obese adolescents.
The investigators reported "encouraging" outcomes in the more than 240 patients who were, on average, 17 years old, finding "few short-term complications" in the 30 days following treatment.
Apollo Endosurgery to buy Allergan’s obesity biz for up to $110M
Weight loss: USGI launches ambitious study of incision-free bariatric surgery
USGI Medical will enroll up to 350 patients in an FDA-approved clinical trial of the g-Cath EZ suture anchor delivery catheter, an incision-free bariatric surgery technology that has already been used on more than 2,000 patients, mostly in Europe.
Reimbursement process begins in Switzerland, Germany for GI Dynamics’ EndoBarrier
GI Dynamics (ASX:GID) said Swiss and German regulators took the 1st steps toward reimbursement in those countries for its EndoBarrier weight loss and diabetes device.
Weight loss: FDA asks for more info on EnteroMedics’ Maestro implant
mHealth weight-loss app raises $18M in Series A round
MyFitnessPal, a San Francisco software developer with a namesake smartphone app, raised its 1st round of funding, today touting an $18 million Series A round led by Kleiner Perkins Caufield & Byers with participation by Accel Partners.
The company has been profitable since its inception, according to a press statement, and this marks the 1st time that it’s looked outside for funding.